Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension Due to Left Ventricular Dysfunction (MELODY-1)

This study has been completed.
Information provided by (Responsible Party):
Actelion Identifier:
First received: February 21, 2014
Last updated: December 15, 2015
Last verified: December 2015
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.

Condition Intervention Phase
Pulmonary Hypertension
Drug: Macitentan
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

Resource links provided by NLM:

Further study details as provided by Actelion:

Primary Outcome Measures:
  • Proportion of subjects experiencing significant fluid retention or worsening in NYHA functional class from baseline [ Time Frame: Baseline to End of Study, up to Week 12 (plus post-treatment safety follow-up of at least 30 days after permanet discontinuation of study treatment) ] [ Designated as safety issue: Yes ]
    Significant fluid retention, defined as one of the following: a.Increase in body weight at any time by ≥ 5% or ≥ 5 kg from baseline due to fluid overload. b.Parenteral administration of diuretics.

Secondary Outcome Measures:
  • Percentage of change from baseline in pulmonary vascular resistance (PVR) to Week 12 [ Time Frame: Baseline to Week 12 ] [ Designated as safety issue: No ]
    PVR was assessed at rest by right heart catheterization

Enrollment: 60
Study Start Date: July 2014
Study Completion Date: November 2015
Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Macitentan
oral tablet, 10 mg once daily.
Drug: Macitentan
oral tablet, 10 mg once daily
Other Name: ACT-064992
Placebo Comparator: Placebo
Matching placebo, once daily.
Drug: Placebo
matching placebo
Other Name: matching placebo


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males and Females >=18 years of age
  2. Subjects with combined pre-and post-capillary Pulmonary Hypertension (CpcPH) due to left ventricular dysfunction (subset of WHO groups 2.1 and 2.2)
  3. Optimized diuretic therapy

Exclusion Criteria:

  1. Types of Pulmonary Hypertension other than WHO groups 2.1 and 2.2 (Nice classification)
  2. Administration of PAH-specific therapy (i.e., Endothelin receptor antagonists (ERAs), Prostanoids, Phosphodiesterase 5 (PDE-5) inhibitors, guanylate cyclase stimulators)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02070991

  Show 32 Study Locations
Sponsors and Collaborators
Study Chair: Sébastien Roux, PhD Actelion
  More Information

Responsible Party: Actelion Identifier: NCT02070991     History of Changes
Other Study ID Numbers: AC-055G201 
Study First Received: February 21, 2014
Last Updated: December 15, 2015
Health Authority: Switzerland: Swissmedic
United States: Food and Drug Administration
Czech Republic: State Institute for Drug Control
Germany: Federal Institute for Drugs and Medical Devices
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Belgium: Federal Agency for Medicinal Products and Health Products
Italy: The Italian Medicines Agency
Israel: Ethics Commission
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Austria: Federal Office for Safety in Health Care
Canada: Health Canada

Keywords provided by Actelion:
pre- and post-capillary pulmonary hypertension

Additional relevant MeSH terms:
Hypertension, Pulmonary
Ventricular Dysfunction
Ventricular Dysfunction, Left
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Heart Diseases
Endothelin A Receptor Antagonists
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Endothelin B Receptor Antagonists processed this record on January 14, 2017